Development of an antibody fused with an antimicrobial peptide targeting Pseudomonas aeruginosa: A new approach to prevent and treat bacterial infections.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
14
04
2023
accepted:
12
08
2023
revised:
19
09
2023
medline:
20
9
2023
pubmed:
7
9
2023
entrez:
7
9
2023
Statut:
epublish
Résumé
The increase in emerging drug resistant Gram-negative bacterial infections is a global concern. In addition, there is growing recognition that compromising the microbiota through the use of broad-spectrum antibiotics can impact long term patient outcomes. Therefore, there is the need to develop new bactericidal strategies to combat Gram-negative infections that would address these specific issues. In this study, we report and characterize one such approach, an antibody-drug conjugate (ADC) that combines (i) targeting the surface of a specific pathogenic organism through a monoclonal antibody with (ii) the high killing activity of an antimicrobial peptide. We focused on a major pathogenic Gram-negative bacterium associated with antibacterial resistance: Pseudomonas aeruginosa. To target this organism, we designed an ADC by fusing an antimicrobial peptide to the C-terminal end of the VH and/or VL-chain of a monoclonal antibody, VSX, that targets the core of P. aeruginosa lipopolysaccharide. This ADC demonstrates appropriately minimal levels of toxicity against mammalian cells, rapidly kills P. aeruginosa strains, and protects mice from P. aeruginosa lung infection when administered therapeutically. Furthermore, we found that the ADC was synergistic with several classes of antibiotics. This approach described in this study might result in a broadly useful strategy for targeting specific pathogenic microorganisms without further augmenting antibiotic resistance.
Identifiants
pubmed: 37676873
doi: 10.1371/journal.ppat.1011612
pii: PPATHOGENS-D-23-00632
pmc: PMC10508631
doi:
Substances chimiques
Immunoconjugates
0
Antibodies, Monoclonal
0
Anti-Bacterial Agents
0
Antimicrobial Peptides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1011612Informations de copyright
Copyright: © 2023 Johnson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests: J.D., A.W., H.T., K.V., and Z.S. are employees of Visterra. O.P. and K.J. were employees and K.L. was a contractor of Visterra when this work was completed.
Références
Evol Appl. 2015 Mar;8(3):273-83
pubmed: 25861385
Nature. 2015 Nov 19;527(7578):323-8
pubmed: 26536114
Front Med Technol. 2020 Dec 11;2:610997
pubmed: 35047892
BioDrugs. 2018 Oct;32(5):465-480
pubmed: 30132210
Biochemistry. 2020 Nov 3;59(43):4202-4211
pubmed: 33085893
J Infect Dis. 1997 Mar;175(3):621-32
pubmed: 9041334
J Antimicrob Chemother. 2010 May;65(5):876-87
pubmed: 20233778
Antibodies (Basel). 2018 Jan 04;7(1):
pubmed: 31544858
Protein Pept Lett. 2014 Apr;21(4):357-67
pubmed: 24164267
Lancet Infect Dis. 2010 Sep;10(9):597-602
pubmed: 20705517
Biochim Biophys Acta. 2013 Jun;1828(6):1457-70
pubmed: 23462641
Cell Mol Life Sci. 2003 Apr;60(4):711-20
pubmed: 12785718
J Clin Invest. 2014 Oct;124(10):4212-8
pubmed: 25271726
Infect Immun. 2010 Feb;78(2):746-55
pubmed: 19995892
Sci Transl Med. 2015 Jul 22;7(297):297ra114
pubmed: 26203082
BMC Infect Dis. 2022 May 24;22(1):491
pubmed: 35610601
J Am Chem Soc. 2004 Mar 10;126(9):2670-1
pubmed: 14995162
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Trends Mol Med. 2017 Feb;23(2):135-149
pubmed: 28126271
Lancet. 2001 Jul 21;358(9277):207-8
pubmed: 11476839
PLoS Biol. 2019 Oct 23;17(10):e3000397
pubmed: 31644535
N Engl J Med. 2010 May 13;362(19):1804-13
pubmed: 20463340
Antimicrob Agents Chemother. 2010 Mar;54(3):1117-24
pubmed: 20028824
Chembiochem. 2013 Jul 22;14(11):1316-22
pubmed: 23828687
Nat Rev Microbiol. 2011 Apr;9(4):233-43
pubmed: 21358670
Gut. 2013 Sep;62(9):1295-305
pubmed: 22760006
Antimicrob Agents Chemother. 1987 Jul;31(7):1054-60
pubmed: 3116917
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20747-52
pubmed: 24248354
ACS Chem Biol. 2014 Sep 19;9(9):2003-7
pubmed: 25058470
Infect Immun. 2006 Nov;74(11):6339-47
pubmed: 16966409
Trends Cancer. 2023 Apr;9(4):339-354
pubmed: 36746689
PLoS One. 2012;7(10):e46648
pubmed: 23077517
Chemotherapy. 2010;56(6):492-500
pubmed: 21099222
Crit Care. 2006;10(4):R114
pubmed: 16882337
Antimicrob Agents Chemother. 2011 Aug;55(8):3929-31
pubmed: 21646490
Front Cell Infect Microbiol. 2022 Mar 15;12:823684
pubmed: 35372099
Annu Rev Biochem. 2002;71:635-700
pubmed: 12045108
PLoS One. 2008 Sep 16;3(9):e3217
pubmed: 18795096
Pharmaceuticals (Basel). 2013 Nov 28;6(12):1543-75
pubmed: 24287494
Nat Microbiol. 2019 Sep;4(9):1450-1456
pubmed: 31133751
Methods Mol Biol. 2017;1548:427-435
pubmed: 28013523
Future Med Chem. 2016 Jun;8(10):1017-25
pubmed: 27328129
Clin Microbiol Rev. 2019 Aug 28;32(4):
pubmed: 31462403
Nat Rev Microbiol. 2020 May;18(5):275-285
pubmed: 31745331